论文部分内容阅读
[目的]分析卡培他滨联合奥沙利铂方案对比氟尿嘧啶(5-Fu)联合奥沙利铂方案(FOLFOX)治疗结直肠癌的疗效与安全性。[方法 ]在Pubmed、EMBase数据库、万方数据库、中国知网、Cochrane图书馆上进行检索,时间2005年1月至2015年12月,对符合纳入标准的随机对照试验进行质量评价、数据提取,并应用Revman 5.3进行meta分析。[结果]共纳入6个随机对照试验,共2463例患者,卡培他滨组与氟尿嘧啶组完全缓解率(CR)(OR=0.90,95%CI:0.39~2.10,P=0.81)、部分缓解率(PR)(OR=0.81,95%CI:0.65~1.00,P=0.84)差异均无统计学意义。卡培他滨组在中位无进展生存期(m PFS)(HR=1,95%CI:0.97~1.15,P=0.21)、中位总生存期(m OS)(HR=1,95%CI:0.98~1.18,P=0.14)方面表现出与5-Fu组相似结果。在安全性方面,卡培组有较高的手足综合征发生风险,而口腔黏膜炎、中性粒细胞减少方面较5-Fu组发生率低,差异均有统计学意义(P<0.01),其他毒副反应两组差异不明显。[结论]卡培他滨联合奥沙利铂治疗结直肠癌疗效与5-Fu组相近,且毒副反应可接受及处理。
[Objective] To analyze the efficacy and safety of capecitabine combined with oxaliplatin in the treatment of colorectal cancer with 5-fluorouracil combined with oxaliplatin (FOLFOX). [Methods] The data of Pubmed, EMBase, Wanfang, CNKI and Cochrane databases were searched from January 2005 to December 2015. The randomized controlled trials that met the inclusion criteria were evaluated for quality, data extraction, And apply Revman 5.3 for meta-analysis. [Results] A total of 6 randomized controlled trials were included. A total of 2463 patients were given capecitabine and fluorouracil with complete remission (CR) (OR = 0.90, 95% CI: 0.39-2.10, P = 0.81) Rate (PR) (OR = 0.81, 95% CI: 0.65-1.00, P = 0.84) showed no significant difference. The median progression-free survival (m PFS) was significantly higher in the capecitabine group (HR = 1,95% CI: 0.97 to 1.15, P = 0.21) CI: 0.98-1.18, P = 0.14) showed similar results as the 5-Fu group. In terms of safety, capecitabine group had a higher risk of hand-foot syndrome, while the incidence of oral mucositis and neutropenia was lower than that of 5-Fu group (P <0.01) Other side effects of the two groups were not significantly different. [Conclusion] The efficacy of capecitabine combined with oxaliplatin in treating colorectal cancer is similar to 5-Fu group, and the side effects are acceptable and manageable.